アルツハイマー病の非典型的臨床病理学的形態において,ロカス・コエルーレウスの脆弱性がより高い
Sara Rose Dunlop1, Billie J Matchett1, Alexander F Mannsbart1
1Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|February 13, 2026
まとめ
ロカス・コレュレウス (LC) はアルツハイマー病 (AD) で退化し,非典型的なAD形態ではより大きな損失を伴う. この研究では,ADサブタイプにおけるLC変性を定量化し,明確なパターンと予測要因を明らかにしました.
科学分野:
- 神経科学は神経科学である.
- 神経病理学 神経病理学
- アルツハイマー病の研究
背景:
- ロカス・コエルーレウス (LC) は,アルツハイマー病 (AD) の早期変性を受けます.
- 様々なADの臨床病理学的なサブタイプにおけるLC変性の特定のパターンはよく理解されていません.
研究 の 目的:
- アルツハイマー病における lokus coeruleus 変性の範囲と神経解剖学的分布を調査する.
- ADにおけるLCニューロン喪失に関連した臨床病理学的および人口学的要因を特定する.
主な方法:
- デジタル病理学を用いて,ニューロン密度とロカス・コエルーレウスの面積を定量化しました.
- 3つの神経解剖学的レベルでのアルツハイマー病症例の大規模なシリーズを分析しました.
主要な成果:
- ヒッポカンプス・スパリング・ADは,典型的なおよびリンビック・ドミナント・ADと比較して,より大きな中部LCの脆弱性を示した.
- 発症時の年齢はロストラルLCのニューロン密度を予測し,ブラークステージ,脳体重,ルイ病,および発症時の年齢は中間のLCの変動性を予測した.
- 記憶喪失症ではないAD症例は,記憶喪失症患者よりもロストラルLCのニューロン密度が低いことを示した.
結論:
- Locus coeruleusの退化は,非典型的なアルツハイマー病のプレゼンテーションではより顕著です.
- 発見は,ヒポカムプス・スパアリング・AD,若発性AD,および非記憶性ADの形態において,より大きなLC脆弱性を強調しています.
関連する概念動画
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Cerebral Edema ll: Pathophysiology
19
Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this...
19
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35


